DE69636907D1 - Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose - Google Patents

Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose

Info

Publication number
DE69636907D1
DE69636907D1 DE69636907T DE69636907T DE69636907D1 DE 69636907 D1 DE69636907 D1 DE 69636907D1 DE 69636907 T DE69636907 T DE 69636907T DE 69636907 T DE69636907 T DE 69636907T DE 69636907 D1 DE69636907 D1 DE 69636907D1
Authority
DE
Germany
Prior art keywords
cholesterol
atherosclerosis
lezithine
azetyl
transferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636907T
Other languages
English (en)
Other versions
DE69636907T2 (de
Inventor
Silvia Santamarina-Fojo
M Hoeg
Bryan Brewer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of DE69636907D1 publication Critical patent/DE69636907D1/de
Application granted granted Critical
Publication of DE69636907T2 publication Critical patent/DE69636907T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Confectionery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
DE69636907T 1995-11-09 1996-11-08 Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose Expired - Lifetime DE69636907T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US640095P 1995-11-09 1995-11-09
US6400P 1995-11-09
PCT/US1996/018159 WO1997017434A2 (en) 1995-11-09 1996-11-08 The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis

Publications (2)

Publication Number Publication Date
DE69636907D1 true DE69636907D1 (de) 2007-03-29
DE69636907T2 DE69636907T2 (de) 2007-11-22

Family

ID=21720680

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636907T Expired - Lifetime DE69636907T2 (de) 1995-11-09 1996-11-08 Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose

Country Status (8)

Country Link
US (1) US6635614B1 (de)
EP (1) EP0871713B1 (de)
AT (1) ATE353957T1 (de)
AU (1) AU728257B2 (de)
CA (1) CA2236982C (de)
DE (1) DE69636907T2 (de)
ES (1) ES2283007T3 (de)
WO (1) WO1997017434A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69836626T2 (de) * 1997-04-11 2007-04-05 Takeda Pharmaceutical Co. Ltd. Proteine mit lecithin-cholesterin acetyltransferase-ähnlicher aktivität, deren herstellung und verwendung
AU5931600A (en) * 1999-07-14 2001-02-05 Betagene, Inc. Lcat recombinant cell line compositions and methods
WO2003040369A2 (fr) * 2001-09-17 2003-05-15 Molecular Engines Laboratories Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments
WO2003062416A1 (fr) * 2002-01-21 2003-07-31 Takeda Chemical Industries, Ltd. Procede de criblage d'agents preventifs et de remedes pour l'arteriosclerose
SE0201581D0 (sv) 2002-05-29 2002-05-29 Scandinavian Biotechnology Res New improved acyltransferase
CA2787343C (en) * 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
EP2522721B1 (de) * 2007-07-26 2016-05-04 Amgen, Inc Modifizierte Lecithin-Cholesterin-Acyltransferase-Enzyme
BRPI1014405A2 (pt) 2009-04-29 2016-04-05 Amarin Corp Plc composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso
US8492108B2 (en) * 2009-06-12 2013-07-23 Bruce J. Auerbach Methods of treating anemia and red blood cell dysfunction with lecithin cholesterol acyltransferase
JP6635655B2 (ja) 2011-12-08 2020-01-29 アムジエン・インコーポレーテツド ヒトｌｃａｔ抗原結合タンパク質および治療法におけるそれらの使用
US10495652B1 (en) * 2012-04-13 2019-12-03 Roar Holding Llc Determination of LCAT
SG11202003835PA (en) * 2017-11-07 2020-05-28 Alphacore Pharma Llc Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943527A (en) * 1985-10-04 1990-07-24 California Biotechnology Inc. Mature apoai protein production under serum free culturing conditions
EP0239631A4 (de) * 1985-10-04 1989-01-12 Biotech Res Partners Ltd Rekombinante apolipoproteine und verfahren.
US5049488A (en) * 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
DE4128288A1 (de) 1991-08-27 1993-03-04 Boehringer Ingelheim Kg Verwendung von paf-antagonisten zur behandlung und diagnose von cholestase und anderen krankheiten, die durch einen erhoehten lipoprotein-x spiegel gekennzeichnet sind
WO1993025581A1 (en) * 1992-06-12 1993-12-23 N.V. Innogenetics S.A. New peptides and proteins, process for their preparation and their use as cholesterol acceptors
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
FR2718329B1 (fr) 1994-03-21 2002-09-20 Rhone Poulenc Rorer Sa Lapin transgénique sensibilisé aux dyslipoprotéinémies.
FR2731710B1 (fr) 1995-03-14 1997-04-30 Rhone Poulenc Rorer Sa Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique

Also Published As

Publication number Publication date
CA2236982A1 (en) 1997-05-15
AU728257B2 (en) 2001-01-04
WO1997017434A3 (en) 1997-06-19
US6635614B1 (en) 2003-10-21
DE69636907T2 (de) 2007-11-22
WO1997017434A2 (en) 1997-05-15
AU7729396A (en) 1997-05-29
ATE353957T1 (de) 2007-03-15
EP0871713B1 (de) 2007-02-14
CA2236982C (en) 2010-07-27
EP0871713A2 (de) 1998-10-21
ES2283007T3 (es) 2007-10-16

Similar Documents

Publication Publication Date Title
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69616333T2 (de) Thip zur behandlung von schlafstörungen
DE69636907D1 (de) Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose
BG103190A (en) Substituted pyrimidine derivatives and their pharmaceutical application
PT841928E (pt) Formulacao de libertacao prolongada de d-trep-metilfenidato
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE308327T1 (de) Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
DE69835823D1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus-interferon
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
DE68913667D1 (de) Imidazole für die Behandlung von Atherosclerose.
DE69526437D1 (de) Transdermal verabreichbare zubereitung zur behandlung von störungen des harnlassens
DE69530403D1 (de) Analogen des keratinozytenwachstumfaktors
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
ATE271865T1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
DE69129953D1 (de) Verwendung von Bisphosphonsäure zur Behandlung von Störungen des Kalziummetabolismus
TR199902192T2 (xx) Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
ATE202552T1 (de) Benzamide für behandlung von neurodegenerativen störungen
ATE236630T1 (de) Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten
DE68903930D1 (de) Lipidemulsion zur behandlung von aids.
DE68908445D1 (de) Mittel zur behandlung von lebererkrankungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition